PL2046354T3 - Preparat z Aphanizomenon flos aquae, wyciągi i oczyszczone składniki tego preparatu do leczenia zaburzeń neurologicznych, zaburzeń zwyrodnieniowych układu nerwowego i zaburzeń nastroju - Google Patents

Preparat z Aphanizomenon flos aquae, wyciągi i oczyszczone składniki tego preparatu do leczenia zaburzeń neurologicznych, zaburzeń zwyrodnieniowych układu nerwowego i zaburzeń nastroju

Info

Publication number
PL2046354T3
PL2046354T3 PL07764849T PL07764849T PL2046354T3 PL 2046354 T3 PL2046354 T3 PL 2046354T3 PL 07764849 T PL07764849 T PL 07764849T PL 07764849 T PL07764849 T PL 07764849T PL 2046354 T3 PL2046354 T3 PL 2046354T3
Authority
PL
Poland
Prior art keywords
neurodegenerative
neurological
treatment
extracts
preparation
Prior art date
Application number
PL07764849T
Other languages
English (en)
Inventor
Stefano Scoglio
Franco Canestrari
Serena Benedetti
Yanina Benedetti
Maria Delgado-Esteban
Original Assignee
Nutratec S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutratec S R L filed Critical Nutratec S R L
Publication of PL2046354T3 publication Critical patent/PL2046354T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07764849T 2006-06-27 2007-06-26 Preparat z Aphanizomenon flos aquae, wyciągi i oczyszczone składniki tego preparatu do leczenia zaburzeń neurologicznych, zaburzeń zwyrodnieniowych układu nerwowego i zaburzeń nastroju PL2046354T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81659306P 2006-06-27 2006-06-27
EP07764849A EP2046354B1 (en) 2006-06-27 2007-06-26 Aphanizomenon flos aquae preparation, extracts and purified components thereof for the treatment of neurological, neurodegenerative and mood disorders
PCT/EP2007/005622 WO2008000430A2 (en) 2006-06-27 2007-06-26 Alphanizomenon flos aquae preparation, extracts and purified components thereof for the treatment of neurological, neurodegenerative and mood disorders

Publications (1)

Publication Number Publication Date
PL2046354T3 true PL2046354T3 (pl) 2012-01-31

Family

ID=38529410

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07764849T PL2046354T3 (pl) 2006-06-27 2007-06-26 Preparat z Aphanizomenon flos aquae, wyciągi i oczyszczone składniki tego preparatu do leczenia zaburzeń neurologicznych, zaburzeń zwyrodnieniowych układu nerwowego i zaburzeń nastroju

Country Status (20)

Country Link
US (1) US9522167B2 (pl)
EP (1) EP2046354B1 (pl)
JP (1) JP5259585B2 (pl)
KR (1) KR20090035490A (pl)
CN (1) CN101478980B (pl)
AT (1) ATE519491T1 (pl)
AU (1) AU2007264042B2 (pl)
CA (1) CA2656154C (pl)
DK (1) DK2046354T3 (pl)
ES (1) ES2370533T3 (pl)
HR (1) HRP20110771T1 (pl)
IL (1) IL196132A (pl)
MY (1) MY146594A (pl)
PL (1) PL2046354T3 (pl)
PT (1) PT2046354E (pl)
RS (1) RS52072B (pl)
RU (1) RU2441663C2 (pl)
SI (1) SI2046354T1 (pl)
WO (1) WO2008000430A2 (pl)
ZA (1) ZA200900747B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20070391A1 (it) * 2007-06-05 2008-12-06 Medestea Res & Production S P Composizione di integratore alimentare,farmaco o dispositivo medicale e suo impiego per sopprimere l'appetito, migliorare tono ed umore, con attivita antidepressiva naturale e con effetto antiastenico
KR100969325B1 (ko) * 2010-02-08 2010-07-09 인천대학교 산학협력단 홍조류로부터 비독성 자외선 차단용 추출물을 제조하는 방법 및 이를 이용한 비독성 자외선 차단제
US20140199380A1 (en) * 2010-05-11 2014-07-17 Benzion Geshuri Pharmaceutical composition comprising an algae adapted to increase the efficacy of an enzymatic inhibitor
US8906361B2 (en) * 2011-03-28 2014-12-09 John V. Cappello Anti-aging formulations
CU23963B1 (es) * 2011-07-01 2013-12-11 Ct De Ingeniería Genética Y Biotecnología Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas
EP3362077A1 (en) * 2015-09-03 2018-08-22 SCOGLIO, Stefano Cyanobacterial microalgae, phycocyanin and phycocyanobilin to beneficially inhibit the activity of the udp-gdh enzyme while significantly increasing the absorption and circulation of curcumin
JP7257479B2 (ja) * 2016-04-27 2023-04-13 長瀬産業株式会社 安定化されたマイコスポリン様アミノ酸を含有する溶液、およびその製造方法
JP6964707B2 (ja) * 2016-04-27 2021-11-10 長瀬産業株式会社 安定化されたマイコスポリン様アミノ酸を含有する溶液、およびその製造方法
JP6719267B2 (ja) * 2016-04-27 2020-07-08 長瀬産業株式会社 安定化されたマイコスポリン様アミノ酸を含有する溶液、およびその製造方法
EP3452073A1 (en) * 2016-05-02 2019-03-13 Stefano Scoglio The use of phycocyanins, purified or as present in cyanobacterial microalgae or extracts thereof, as prebiotics, to enhance the viability, gastrointestinal survival, pathogen-fighting ability, and the overall health-enhancing properties of probiotic cultures and products.
CA3052737A1 (en) 2017-09-06 2019-03-14 Stefano Scoglio The transdermal use of cyanobacterial algae, and/or extracts thereof, via low or high intensity transporation devices for beauty and health enhancing purposes
KR102003911B1 (ko) * 2018-02-23 2019-07-25 씨제이제일제당 주식회사 마이코스포린 유사 아미노산을 생산하는 미생물 및 이를 이용한 마이코스포린 유사 아미노산의 생산방법
CN108484438A (zh) * 2018-03-06 2018-09-04 佛山科学技术学院 一种从紫菜中提取类菌胞素氨基酸的方法
CN108421031A (zh) * 2018-04-13 2018-08-21 桂林医学院 藻蓝蛋白在制备防治帕金森病药物中的应用
CN108752445B (zh) * 2018-06-20 2021-04-30 广东药科大学 一种螺旋藻蛋白的制备工艺及其神经保护用途
CN111700903B (zh) * 2020-08-07 2022-03-11 华侨大学 一种紫菜多糖的应用及紫菜多糖的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5865216A (ja) * 1981-09-16 1983-04-18 Dainippon Ink & Chem Inc 抗腫瘍剤
US5455276A (en) * 1993-05-20 1995-10-03 Sabelli; Hector C. Method for treating depression
US6814961B1 (en) * 2001-05-14 2004-11-09 Gitte S. Jensen Method for enhancing stem cell trafficking
AU2006261852B2 (en) * 2005-06-24 2012-07-19 Desert Lake Technologies Purified component of blue-green algae and method of use

Also Published As

Publication number Publication date
CN101478980A (zh) 2009-07-08
ATE519491T1 (de) 2011-08-15
AU2007264042A1 (en) 2008-01-03
PT2046354E (pt) 2011-11-09
RU2441663C2 (ru) 2012-02-10
MY146594A (en) 2012-08-30
RS52072B (en) 2012-06-30
DK2046354T3 (da) 2011-10-31
WO2008000430A3 (en) 2008-03-27
RU2008151175A (ru) 2010-06-27
WO2008000430A2 (en) 2008-01-03
AU2007264042B2 (en) 2012-01-12
JP2009541388A (ja) 2009-11-26
CA2656154A1 (en) 2008-01-03
SI2046354T1 (sl) 2011-11-30
EP2046354A2 (en) 2009-04-15
CA2656154C (en) 2017-02-28
JP5259585B2 (ja) 2013-08-07
KR20090035490A (ko) 2009-04-09
EP2046354B1 (en) 2011-08-10
IL196132A0 (en) 2009-09-22
ZA200900747B (en) 2010-05-26
ES2370533T3 (es) 2011-12-19
US9522167B2 (en) 2016-12-20
CN101478980B (zh) 2013-03-20
US20090311286A1 (en) 2009-12-17
IL196132A (en) 2014-06-30
HRP20110771T1 (hr) 2011-11-30

Similar Documents

Publication Publication Date Title
ZA200900747B (en) Alphanizomenon flos aquae preparation, extracts and purified components thereof for the treatment of neurological, neurodegenerative and mood disorders
TNSN08400A1 (en) Organic compounds and their uses
WO2007038610A3 (en) Use of natural products for treatment of neurological disorders
TN2010000137A1 (en) Spiropyrrolidines and their use against hcv and hiv infection
TW200616656A (en) Angelicae sinensis extracts useful for treatment of cancers
WO2006119295A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
MY149492A (en) Immunoglobulins directed against nogo
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
WO2004041203A3 (en) Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
WO2007130383A3 (en) Compositions and treatments using pyridazine compounds and secretases
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
WO2008000513A3 (en) Peptide compounds for the treatment of hyperexcitability disorders and diseases associated with ion channel dysfunction
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
EP2152865A4 (en) METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS
EP2069377A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES AND SKIN FUNCTIONAL DISORDERS
ZA200800981B (en) Use of SDF-1 for the treatment and/or prevention of neurological diseases
EA201101579A1 (ru) Имидазо[1,2-а]пиридин-2-ил-фенил производные для лечения рака
TW200621799A (en) Acylated nonadepsipeptides II
MX2009009451A (es) Extracto bacteriano para trastornos del tracto digestivo o uranio y proceso para su preparacion.
SG162829A1 (en) Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
WO2008039409A3 (en) Methods and kits for use in the treatment and prevention of diseases or conditions of the immune system or infectious diseases
IL194353A0 (en) Lysobactin amides
WO2010083311A3 (en) Compositions and methods of use
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases